Gary.boutte1941@gmail.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News this morning…
Potential suitor who expressed interest……licensing partners…..waiting for results!
Carrot still out there, needs nibbling.
Good morning, I think this may just be an update on the 8-K. Last year they indicated the RS is pending, now same update with 2023/2024.
In the past when one was presented, they immediately gave the FINRA 20 day notification to stockholders. Sadly it plunged within days, losing most of your value.
I’m hanging in there, we may be in for a surprise with a positive PR.
I think they just reapplied for the RS, Finra didn’t accept the last one in 2022 because the previous 2 didn’t work out, the PPS went back to trips again.
If Finra accepts they are obligated to give shareholders 20 day notice.
Just observing……RS is to strengthen the company, not become your ATM.
Agree, last RS had a 20 day notice that FINRA published to stockholders.
Great update, thanks for keeping shareholders informed!
Don’t have crystal ball on when to holdum and when to foldum.
With my shares I accumulate $2,500 on every .0001 tick!
I do agree we may see copper if the news is positive.
Not a trader, 82 year old watcher. Just remain patient and don’t get caught up in the negatives. Good things will happen!
I’ve seen the good, the bad and the ugly! Holding 25M and this is my last hurrah!
1st time buyer at .0003 years ago, sold at .09 with less than 1/2M shares.
Good luck and stay patient……..good things will happen!
Not calling you out, love your DD, you make a great point for most to understand. New people come on and say things that are head scratchers without looking at company.
Thanks for keeping it real!
Been here a while, not once did PPCB say they had a cure for cancers.
The findings show it halts cancer cells ability to invade and metastasize.
Not a cure, just a control to prolong life.
Go to website to get updates!
Hi Kindo
Sent to time out for a few years!
Still holding Ppcb with 25m, hated the RS’s in the past.
Let me know when it’s a good time to get out…….lol
Nice hearing from you.
Patience prevails!
Almost bought more EVTI, watching news and heard Gannon was pardoned by the president.....it was Bannon! lol
Maybe just "RAT"..
Last hurrah!!!! I'm a little fish trying to keep his head above water.
Swamprat retired and away from the great Atchafalaya Swamp.
Now living in Arizona, guess I need to change my handle to Sandrat!!! lol
Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients
DOWNLOAD AS PDFJanuary 18, 2021
MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company has received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors in pancreatic and ovarian cancers. The letters of interest were confirmed by Drs Natalia Luque Caro and Fernando Gálvez Montosa, medical oncologists specializing in pancreatic and ovarian cancers, respectively, from the University Hospital of Jaén, in Granada, Spain. The evaluation will most likely be conducted as separate Phase IIa proof of concept (POC), multi-trial center studies for each target indication.
The expressions of interest were confirmed after evaluation of Propanc’s scientific literature supporting the use of proenzymes in pancreatic and ovarian cancers. The Phase IIa POC studies will be conducted after a Phase Ib dose escalation study evaluating the tolerability and activity of proenzyme therapy in patients with advanced solid tumors is completed, planned for 2021, at the Peter Mac Cancer Center, Melbourne, Australia.
“Receiving expressions of interest from Drs Caro and Montoya at the University Hospital of Jaén provides important infrastructure to plan our multi-trial center studies, which will likely require up to 60 patients for each study in pancreatic and ovarian cancers, which is why we were thinking of running these trials in Europe, due to the larger patient populations,” said James Nathanielsz, Propanc’s Chief Executive Officer. “By running multi-trial centre studies for our Phase IIa studies, we ensure that we have sufficient numbers to complete the trials more efficiently than if we ran the trials in Australia, alone. Furthermore, the University Hospital of Jaén is located in Granada, Spain, and is a well-known biopharmaceutical hub with a strong reputation among multi-national companies. We look forward to a potential collaboration with the clinical trial investigators from this reputable institution.”
Whales moved to new feeding grounds, finally got rid of my 8m shares....and made a little profit.
Last one standing............ turn off the lights!
Good bye and good night.
Jan 11, 2021
Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers
Jack dumped a ton the last few days, think this is over.
Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111.2B Global Metastatic Cancer Market
DOWNLOAD AS PDFDecember 30, 2020
MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Proenzymes Optimization Project 1 (“POP1”) joint research and drug discovery program advanced towards producing commercial scale quantities of the two proenzymes trypsinogen and chymotrypsinogen. The Company’s product candidate is targeting the global metastatic cancer treatment market, projected to be worth US$111.2 Billion by 2027, according to current analysis by Emergen Research.
The program’s lead research scientist, Mr. Aitor González, synthesized and purified both proenzymes in the laboratory. Once purified, the proenzymes were lyophilized (freeze dried) and each formed a stable, dry white powder. Mr. González then determined the sequence of proteins of each proenzyme by mass spectrometry. He recently started to produce larger quantities of the proenzymes with the objective of establishing their combined anti-cancer effects against pancreatic and colorectal cancers. In addition, research activities were transferred to the MEDINA Foundation Research Center to scale up production. MEDINA is a Non-Profit Research Organization established in 2008 through a public-private alliance between the Regional Government of Andalusia, Spain, the pharmaceutical company Merck Sharp & Dohme de España S.A. (MSD), and the University of Granada. Medina’s scientific platforms support the development of multidisciplinary research programs in Microbiology, Natural Product Chemistry and Screening & Target Validation. For further information, please click on the following link: https://www.medinadiscovery.com/es/
The POP1 program is designed to produce a backup clinical compound to the lead product candidate, PRP. The objective is to produce large quantities of trypsinogen and chymotrypsinogen for commercial use that exhibits minimal variation between lots and without sourcing the proenzymes from animals. Propanc is undertaking the challenging research project in collaboration with the Universities of Jaén and Granada, led by research scientist Mr. Aitor González, supported by Dr. Macarena Perán, Ph.D., representing the Universities and Propanc’s Chief Scientific Officer, Dr. Julian Kenyon, M.D.
Mr. James Nathanielsz, Propanc’s Chief Executive Officer said, “By expanding our product pipeline, our vision is to establish a new product class that provides a solution for the treatment and prevention of many recurring and spreading malignant tumors, perceived as untreatable, with less toxicity compared to standard treatments and no immune suppression. This is critical for patients who are at risk of dying from secondary infection, especially in the context of a global pandemic. Through our PRP development and POP1 drug discovery programs we are making positive steps towards achieving our vision.”
“Despite a challenging year due to the global pandemic, we made significant advancements in producing synthetic recombinant versions of trypsinogen and chymotrypsinogen,” said Dr. Julian Kenyon. “These two active pharmaceutical ingredients combine to form our lead product candidate, PRP, which are currently of animal origin. Our objective is to further stabilize and enhance the combined effects of the two proenzymes when administered to patients.”
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit www.propanc.com.
The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
To view the Company’s “Mechanism of Action” video on its anti-cancer lead product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
Propanc Biopharma Receives First Granted Patent for Method to Treat Cancer Stem Cells from Australian Patent Office
Dec 21, 2020
Its now a pink sheet
Propanc Biopharma Inc OTC Pink
We may see less alerts now.... not QB!!!!
Trump administration will give the airlines a bailout, giving it now would give him a boost....especially with airline personnel.
Stock will climb $4-5 dollars on the news!!
10/01/20 10-K Annual report pursuant to Section 13 and 15(d)
Thanks for informing me, always wondered why they didn't change in the past when they were below the mark..
Propanc Biopharma Inc OTCQB..... this is current.
Source TD Ameritrade Oct 1, 2020
Thought is was not reporting status...
Look at news on this stock that is trying to get QB status and now currently .004
Asia Metals Inc. Finalizes Auditor Selection For OTCQB Qualification
AABB
This is example, just caught my eye on trying to change!!!
Where did you find that information, send a link!!!
QB status means you have to remain current and in good standing.
Pink: No need to keep investors current, should do Quarter filings.
lol....clever.
That's funny, don't care what others say!
Hey Penny, thanks for the kind words. I drank lots of Swamp Water in Louisiana in the past few years, now because of health reasons moved to Arizona. Thanks for noticing I do not promote this stock, made money on PPCB in the past....now thinking it may be the right time to hold a position with over 3M. Thought today would be the ripe time for news...still holding my breath! lol
Good trading and remember, Keep it real!!!!
That would be nice, could happen if the right news hits!
No wall buildup to .005, once we clear .0038 the run begins!
Number 5 on the breakout board, nice time for news (getting eyes on this stock)
Nice volume, news on the horizon!
UAL touched $39.77 today.
New resistance point!!!!!
Agree, just not R/S news..lol
Checked all sources, nothing after hours.... maybe in the morning with that 911 alert! Last time someone did that call it happened a few days later.
This is spring loaded, just the right PR and an investor trolling the stock.
Agree, something is coming...... hoping it's not the R/S..lol
They will hold it because of the volume and upward motion.